Adamed's Arabian adventure
Adamed wants to launch two of its cardiac drugs, Amlozek and Xartan, and Zolafren, a psychiatric medicine, on the Kuwaiti market. The company has signed a deal with a pharmaceutical firm in Kuwait, which will help Adamed with the registration procedure for the drugs. "We predict that the registration process and launching the product on the market will take several months," says Sławomir Mirek, managing director at Adamed.
Adamed already has a business partner in Saudi Arabia. "They are closely connected to the markets in the area of the Persian Gulf. For business to develop in these countries it is crucial to enter the markets of both Saudi Arabia and Kuwait. A simultaneous presence in these countries gives an opportunity to negotiate advantageous conditions in the pharmaceutical tenders in the region," says Mirek.
Adamed's interest in the Persian Gulf came about after a trade mission arranged by the then-Deputy Prime Minister, Marek Pol, and the National Chamber of Commerce at the end of 2003. "It was then when we met our present partner from Saudi Arabia," says Mirek.
"Polish companies are not known on the pharmaceutical market in Kuwait. Our products will work for their reputation themselves. It has to be stressed, however, that the image of Polish companies in Arab countries improved after Poland joined the EU," says Mirek. The value of the medicine market in Kuwait within the group of therapeutic drugs offered by Adamed is $5 (zł.16.7) million. In Saudi Arabia it is three times bigger.
Adamed will reveal the identity of its business partners only when products are launched in the Arabic market in 2006.
Adamed already has a business partner in Saudi Arabia. "They are closely connected to the markets in the area of the Persian Gulf. For business to develop in these countries it is crucial to enter the markets of both Saudi Arabia and Kuwait. A simultaneous presence in these countries gives an opportunity to negotiate advantageous conditions in the pharmaceutical tenders in the region," says Mirek.
Adamed's interest in the Persian Gulf came about after a trade mission arranged by the then-Deputy Prime Minister, Marek Pol, and the National Chamber of Commerce at the end of 2003. "It was then when we met our present partner from Saudi Arabia," says Mirek.
"Polish companies are not known on the pharmaceutical market in Kuwait. Our products will work for their reputation themselves. It has to be stressed, however, that the image of Polish companies in Arab countries improved after Poland joined the EU," says Mirek. The value of the medicine market in Kuwait within the group of therapeutic drugs offered by Adamed is $5 (zł.16.7) million. In Saudi Arabia it is three times bigger.
Adamed will reveal the identity of its business partners only when products are launched in the Arabic market in 2006.
